SPX4,283.74
0.23%Positive
IXIC12,965.34
DJI33,999.04
0.06%Positive
STOXX440.76
FTSE7,541.85
0.35%Positive
N22528,930.33
0.04%Negative

Supernus Pharmaceuticals Inc

SUPN.O

Official Data Partner

Latest Trade: trading higher33.86USD
Change: 0.35
% Change: 1.04%Positive

As of Aug 19 2022. Values delayed up to 15 minutes

Day Range: 33.31 - 33.94
52-Week Range: 23.15 - 34.50

Previous Close: 33.51
Open: 33.54
Volume: 245,283.00
3 Month Average Trading Volume: 7.22
Shares Out (Mil): 53.50
Market Cap: 1,792.63
Forward P/E: 22.80
Dividend Yield: -99,999.99

Key Statistics

2 mean rating - 4 analysts

Sell

Hold

Buy

P/E Excl. Extra Items (TTM): 33.96
Price To Sales (TTM): 2.85
Price To Book (Quarterly): 2.13
Price To Cash Flow (Per Share TTM): 14.96
Total Debt/Total Equity (Quarterly): 47.65
Long Term Debt/Equity (Quarterly): 0.00
Return On Investment (TTM): 5.11
Return On Equity (TTM): 3.52

2021 (millions USD)

About Supernus Pharmaceuticals Inc (SUPN.O)

Company Information

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company's diverse neuroscience portfolio includes treatments for epilepsy, migraine, attention deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. It is also developing a range of CNS product candidates, including potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial portfolio of products includes Trokendi XR (topiramate) and Oxtellar XR (oxcarbazepine) for the treatment of epilepsy. Its APOKYN (apomorphine hydrochloride injection) is a product indicated for the acute, intermittent treatment of hypomobility in patients with advanced Parkinson's disease (PD).

Address

9715 Key West Avenue
ROCKVILLE, MD
20850
United States

Contact Information

+1 (301) 8382500

https://www.supernus.com

Industry

Biotechnology & Drugs

Executive Leadership

Charles W. Newhall: Independent Chairman of the Board
Jack A. Khattar: President, Chief Executive Officer, Secretary, Director
Timothy C. Dec: Chief Financial Officer, Senior Vice President
Padmanabh P. Bhatt: Senior Vice President - Intellectual Property, Chief Scientific Officer
Tami Tillotson Martin: Senior Vice President - Regulatory Affairs
Frank Mottola: Senior Vice President - Quality, GMP Operations and Information Technology
Jonathan Rubin: Senior Vice President, Chief Medical Officer - Research and Development
Carrolee Barlow: Independent Director
Georges Gemayel: Independent Director
Frederick M. Hudson: Independent Director
John M. Siebert: Independent Director